10. Lastly, IMAs have a very unique molecular profile – 80-90% KRAS, and those without KRAS frequently have NRG1 fusions, which are targetable. So fusion testing is essential in IMAs. Pl see https://t.co/jlZPAarQAk. Was a thrill to collaborate with @alexdr
RT @ElizSMcKenna: ICYMI in @CD_AACR, mentioned by @AliSchram in her #Targets19 presentation: Response to ERBB3-Directed Targeted Therapy…
RT @ElizSMcKenna: ICYMI in @CD_AACR, mentioned by @AliSchram in her #Targets19 presentation: Response to ERBB3-Directed Targeted Therapy…
RT @ElizSMcKenna: ICYMI in @CD_AACR, mentioned by @AliSchram in her #Targets19 presentation: Response to ERBB3-Directed Targeted Therapy…